Strategic positioning for clinical trials in 2021

MyMD will commence a Phase 2 clinical trial of MYMD-1 in COVID19 associated depression in 2021. In addition, we expect to advance MYMD-1 into a phase 2 clinical trial for treatment of diabetes, rheumatoid arthritis, Sarcopenia (aging) and multiple sclerosis. We will also execute studies of SUPERA-1R that will enable submission of an Investigational New Drug Application (IND) to the FDA for a Phase 1 clinical trial in epilepsy, addiction, autism and anxiety disorders.

We’re making news in the biotech pharmaceuticals industry

MyMD Pharmaceuticals Announces New MYMD-1 Data From Study Performed by Eurofins Discovery

Study from Eurofins Discovery revealed potential of MYMD-1 as a therapy for fibrosis.

Study Identifies Effects of Temperature Changes on SARS-CoV-2 Transmission

Chief Scientific Officer of MyMD Pharmaceuticals authors study published in peer-reviewed journal.

MyMD Pharmaceuticals Announces Issuance of Key Patent

Patent protects methods of regulating TNF-a to treat cancers and chronic inflammation disorders.

All News

  • This field is for validation purposes and should be left unchanged.